Ovid Therapeutics vs Precigen
Precigen reported revenue of $10 million in fiscal 2025, 1.3 times Ovid Therapeutics' $7 million in fiscal 2025. Ovid Therapeutics' revenue grew 1181.3% in its latest year, and Precigen's grew 146.7%. Ovid Therapeutics had an operating margin of -585.2%, against -1141.1% at Precigen. Free cash flow was −$38 million at Ovid Therapeutics and −$90 million at Precigen.
Side by side
| Ovid Therapeutics | Precigen | |
|---|---|---|
| Latest fiscal year | FY2025, Dec 31, 2025 | FY2025, Dec 31, 2025 |
| Revenue | $7M | $10M |
| Revenue growth | 1,181.3% | 146.7% |
| Revenue growth a year, last 5 years | −10.3% | −21.2% |
| Gross margin | — | — |
| Operating margin | −585.2% | −1,141.1% |
| Net margin | −240.1% | −2,588.2% |
| Free cash flow | −$38M | −$90M |
| Free cash flow margin | −528.6% | −927.6% |
| Return on capital | — | — |
| Net debt to EBITDA | — | — |
| Dividends and buybacks | $0M | $0M |
| Change in diluted share count | — | 16.9% |
| Last close | $2.54 | $4.54 |
| P/E at the last close | — | 45.4× |
| Insider trades, last 12 months | — | — |
| Piotroski F-score | — | 2 of 8 |
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.
Ten years
Revenue
US$ billions, fiscal years
Ovid TherapeuticsPrecigen
Operating margin
Percent of revenue
Ovid TherapeuticsPrecigen
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Ovid TherapeuticsPrecigen
Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Ovid Therapeutics and Precigen pages.